Magnetic Field-Induced Strain of Metamagnetic Heusler Alloy Ni41Co9Mn31.5Ga18.5

Ni41Co9Mn31.5Ga18.5 is a re-entrant and metamagnetic Heusler alloy. In order to investigate the magnetic functionality of polycrystalline Ni41Co9Mn31.5Ga18.5, magnetic field-induced strain (MFIS) measurements were performed. A 0.12% MFIS was observed at 340 K and 10 T. Strict MFISs between 330 and 370 K were observed. These magneto-structural variances acted in concert with the metamagnetic property observed by the magnetization measurements and magneto-caloric property observed by the caloric measurements in applied magnetic fields. The MFISs were proportional to the fourth power of the magnetization, and this result is in agreement with Takahashi’s spin fluctuation theory of itinerant electron magnetism. The investigation of time response of the MFIS was performed by means of water-cooled electric magnet, zero magnetic field to 1.66 T in 8.0 s at 354 K. A 2.2×10−4 MFIS was observed, which was 80% of the MFIS in a 60-s mode. This indicates that a high-speed transition has occurred on applying magnetic fields

Plasma Free Amino Acid Profiling of Five Types of Cancer Patients and Its Application for Early Detection

BACKGROUND: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection. METHODS AND FINDINGS: Plasma samples were collected from approximately 200 patients from multiple institutes, each diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance liquid chromatography (HPLC)-electrospray ionization (ESI)-mass spectrometry (MS). Univariate analysis revealed significant differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC >0.75 for each cancer), regardless of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling. CONCLUSIONS: These findings suggest that PFAA profiling has great potential for improving cancer screening and diagnosis and understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when compared to existing screening methods

腎盂原発腺癌の1例

28歳の女性で腺癌細胞を腸水中に含む腎盂原発腺癌の1例を経験した.原発巣に対し根治的腎摘出術, 残存尿管摘出, 膀胱部分切除術を施行した.補助療法としてシスプラチン, アドリアマイシン, サイクロフォスフママイド(CAP)を用いた多剤併用化学療法を行った.腎摘出後, 約3年経過しているが再発の兆候はなく, CAP療法が有効であったと思われた.A 28-year-old female had adenocarcinoma arising from the renal pelvis with ascites containing adenocarcinoma cells. The primary site was treated with radical nephrectomy, resection of the remnant ureter with a bladder cuff. Combination chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) was performed as an adjuvant therapy. Approximately 3 years after the nephrectomy, she is currently alive with no clinical evidence of recurrence. CAP seems to have been effective in the treatment of the disease